Please note Epocrates will no longer provide this CME offering after December 31, 2015. However this free offering will continue to be available directly from RealCME and there will be no interruption to your account, including credits, certificates and new course offerings.

Please directly access your account by clicking RealCME Health Professional and use the same email address to log in to your account that you have used with EpocratesCME. For security purposes, you will be asked to establish a new password.

An Evidence-based Approach to the Diagnosis and Treatment of COPD: Improving Patient Care


An Evidence-based Approach to the Diagnosis and Treatment of COPD: Improving Patient Care

Topic: Pulmonary Disease
Relevant Terms: Bronchodilators, COPD, Respiratory, Spirometry
Primary Audience: Family and General Practice Physicians, Internal Medicine Physicians, Primary Care Physicians
Launch Date: 30-Dec-11
Credits: 0.75 AMA PRA Category 1 Credit
Expiration Date: The accreditation for this activity has expired.

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Implement evidence-based recommendations for the accurate diagnosis and appropriate treatment of patients with chronic obstructive pulmonary disease (COPD)
  2. Recognize when long-acting therapy is appropriate for patients with frequent COPD symptoms or exacerbations
  3. Develop treatment plans that incorporate patients' needs, preferences, and lifestyle to optimize adherence to treatment


    Amir Sharafkhaneh, MD, PhD
    Associate Professor of Medicine
    Department of Medicine
    Pulmonary and Critical Care Medicine
    Program Director, Sleep Medicine Fellowship Program
    Baylor College of Medicine
    Houston, Texas
    Estimated Time to Complete Activity: 0.75 hours

    Accreditation Statement
    Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Credit Designation
    Integrity Continuing Education designates this Internet activity for 0.75 AMA PRA Category 1 Credits. Physicians should only claim credit commensurate with the extent of their participation in the activity.

    Disclosure of Conflicts of Interest
    Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
    The faculty/planners reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
    Amir Sharafkhaneh, MD, PhD
    Consultant: Dey Pharma, GlaxoSmithKline
    Research/Grants: GlaxoSmithKline
    Speakers' Bureau: Boehringer Ingelheim, Dey Pharma, GlaxoSmithKline, Pfizer
    Sean M. Gregory, PhD, hereby states that he or his spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.


    Method of Participation
    There are no fees for participating and receiving CME credit for this enduring activity. During the period of December 30, 2011 through December 30, 2012, participants must:

    • Read the learning objectives and faculty disclosure
    • Study the educational activity
    • Complete the posttest and evaluation form following the activity
    A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

    Hardware/Software Requirements
    Windows: Internet Explorer 6, Internet Explorer 7, Firefox 1.x and later, Safari 3, Google Chrome, Opera 9.5
    Macintosh: Firefox 1.x and later, Safari 3
    Linux: Firefox 1.x

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integrity Continuing Education, Inc., and Dey Pharma, L.P., do not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education, Inc., and Dey Pharma, L.P. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Commercial Support
    This educational activity is supported by an educational grant from Dey Pharma, L.P.

    Integrity Continuing Education
    For questions about the accreditation of this activity, please contact Integrity Continuing Education at 888-255-1009 or